Promising Tx for HCV, HIV Coinfection

the MPR take:

For patients with hepatitis C virus (HCV) and HIV, drug interactions with antiretroviral therapies and the need to use interferon have limited treatment of these conditions together. In an open-label, nonrandomized, uncontrolled Phase 3 trial of 223 treatment-naive and treatment experienced patients with HCV-HIV coinfection, treatment-naive patients with HCV genotype 2 or 3 received 400mg of sofosbuvir and weight-based ribavirin for 12 weeks, while treatment-naive patients with HCV genotype 1 and treatment-experienced patients with HCV genotype 2 or 3 received the treatment for 24 weeks. 76% of treatment-naive patients with HCV genotype 1, 88% with genotype 2, and 67% with genotype 3 achieved a sustained viral response to treatment after 12 weeks (SVR12); for treatment-experienced patients, 92% with genotype 2 and 94% of the others achieved SVR12. Further studies are needed to confirm these findings in diverse populations of coinfected patients, the study authors note.

Interferon-Free Tx Promising for HCV, HIV Coinfection
Interferon-Free Tx Promising for HCV, HIV Coinfection

Importance: Treatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon. Design, Setting, and Participants: Open-label, nonrandomized, ...

READ FULL ARTICLE From Jamanetwork

Loading links....